

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroTech Medical (Hangzhou) Co., Ltd.**

**微泰醫療器械(杭州)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2235)**

**CHANGE OF JOINT COMPANY SECRETARY,  
AUTHORISED REPRESENTATIVE AND PROCESS AGENT  
AND  
WAIVER FROM STRICT COMPLIANCE WITH  
RULES 3.28 AND 8.17 OF THE LISTING RULES**

The board (the “**Board**”) of directors (“**Director(s)**”) of MicroTech Medical (Hangzhou) Co., Ltd. (the “**Company**”) hereby announces that Mr. Zhang Mengchi (“**Mr. Zhang**”) has tendered his resignation as (i) the joint company secretary of the Company (the “**Joint Company Secretary**”); (ii) an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iii) the authorised representative of the Company for accepting service of process or notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from September 26, 2023.

Mr. Zhang has confirmed that he has no disagreement with the Board and there is no other matter in connection with his resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board further announces that Ms. Chu Pik Man (“**Ms. Chu**”) has been appointed as one of the Joint Company Secretaries, the Authorised Representative and the Process Agent with effect from September 26, 2023. Mr. Duo Bo (“**Mr. Duo**”) will continue to serve as another Joint Company Secretary.

The biographical details of Mr. Duo and Ms. Chu are set out below:

Mr. Duo, aged 31, was appointed as a Joint Company Secretary in April 2021. Mr. Duo served as an investment bank business assistant at Xinjiang Westeast Economic Research Institute (新疆東西部經濟研究院) from August 2015 to February 2016. He then worked at Bode Century Enterprise Management Consulting Co., Ltd. (深圳博得世紀企業管理顧問股份有限公司), serving as investment and financing manager and the head of information disclosure from March 2016 to January 2019. After that, Mr. Duo joined Shenzhen Ruijie Engineering Consulting Co., Ltd. (深圳瑞捷工程諮詢股份有限公司), serving as the securities commissioner from March 2019 to May 2020. Since January 2021, Mr. Duo has been serving as the securities affairs representative and legal affairs officer of our Company.

Mr. Duo received a bachelor's degree in Accounting from Jiujiang University (九江學院) in the PRC in July 2016. Mr. Duo obtained the Securities Qualification Certificate from China Securities Industry Association in March 2015 and was qualified as the secretary of the board of directors by National Equities Exchange and Quotations Co., Ltd., Science and Technology Innovation Board of the Shanghai Stock Exchange (上海證券交易所科創板) and Shenzhen Stock Exchange in December 2017, September 2021 and October 2022, respectively. He obtained the legal professional qualification certificate granted by the Ministry of Justice of the PRC in April 2021.

Ms. Chu is currently an assistant manager of SWCS Corporate Services Group (Hong Kong) Limited. Ms. Chu has over 5 years of experience in the corporate secretarial field. She is a Chartered Secretary, a Chartered Governance Professional and an Associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Ms. Chu holds a bachelor's degree of Business Administration (Honours) in Corporate Governance Concentration from Hong Kong Shue Yan University.

## **WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

Reference is made to the appointment of Mr. Duo as one of the Joint Company Secretaries and the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in relation to the eligibility of Mr. Duo to act as the Joint Company Secretary for a period of three years from the date of the Company's listing (i.e. October 19, 2021) to October 18, 2024 (the “**Waiver Period**”), on the condition that Mr. Zhang, who possesses the qualifications or experience as required under Rules 3.28 and 8.17 of the Listing Rules, is appointed as the Joint Company Secretary and provides assistance to Mr. Duo to acquire the “relevant experience” within the meaning of Rule 3.28 of the Listing Rules and to discharge his duties as the Joint Company Secretary during the Waiver Period. The Waiver will be revoked immediately when Mr. Zhang, during the Waiver Period, ceases to provide assistance to Mr. Duo.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted a new waiver (the “**New Waiver**”) to the Company from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period from the date of appointment of Ms. Chu as the Joint Company Secretary (i.e. September 26, 2023) to October 18, 2024 (i.e. the remaining period of the Waiver Period) (the “**New Waiver Period**”) in relation to the eligibility of Mr. Duo to act as a Joint Company Secretary. The New Waiver is granted on the conditions that:

- (i) Mr. Duo must be assisted by Ms. Chu during the New Waiver Period;
- (ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company; and
- (iii) the Company would publish this announcement disclosing the reasons for, details and conditions of the New Waiver, and the qualification and experience of both Ms. Chu and Mr. Duo.

Before the end of the New Waiver Period, the Company must demonstrate and seek the Stock Exchange’s confirmation that Mr. Duo, having had the benefit of Ms. Chu’s assistance during the New Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The New Waiver will be revoked immediately if and when Ms. Chu ceases to be a Joint Company Secretary. The Stock Exchange may withdraw or change the New Waiver if the Company’s situation changes.

The Board would like to express its gratitude to Mr. Zhang for his contribution to the Company during his tenure of office and welcome Ms. Chu on her new appointment.

By order of the Board  
**MicroTech Medical (Hangzhou) Co., Ltd.**  
**Zheng Pan**  
*Chairman of the Board*

Hangzhou, the PRC, September 26, 2023

*As at the date of this announcement, the executive Directors are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors are Mr. Hu Xubo and Ms. Gao Yun; and the independent non-executive Directors are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.*